Hypertension remains a major global health issue, impacting over 1.4 billion people worldwide [1]. While most cases are classified as essential hypertension, about 5–15% are caused by secondary factors, many of which are related to endocrine issues. Endocrine hypertension (EH) is a type of high blood pressure influenced or driven by hormonal imbalances. These conditions typically result from either excessive or insufficient hormone secretion that governs fluid balance, vascular tone, and sodium metabolism. EH is a potentially treatable form of hypertension, but it is often underdiagnosed and undertreated in healthcare. As awareness of its prevalence and cardiovascular risks grows, there is a renewed focus on early detection and targeted management of EH